



August 25, 2020

To  
The Department of Corporate Services,  
The Bombay Stock Exchange Limited,  
25<sup>th</sup> Floor, Phiroz Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

Dear Sir/Madam,

**Sub: Intimation of the Outcome of Board Meeting – Reg.,**  
**Ref: Our Board Meeting Notice Dated 17<sup>th</sup> August, 2020**

.....

We wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. 25<sup>th</sup> of August, 2020 has Approved Un-Audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2020. A Copy of the results and Limited Review Report for the quarter ended 30.06.2020 issued by the Statutory Auditors M/s. N G Rao & Associates, Chartered Accountants is enclosed for your information.

Kindly acknowledge the receipt of this letter.

Thanking you,

Yours truly,  
**For GAYATRI TISSUE & PAPERS LTD**

**(Dinesh Vemula)**

Company Secretary & Compliance Officer



**Encl:** A Copy of the results and Limited Review Report for the quarter ended 30.06.2020 issued by the Statutory Auditors M/s. N G RAO & Associates, Chartered Accountants, enclosed for your information.

Regd. Office :

**Gayatri Tissue & Papers Limitd**

16/ 137, No. 5, Near Prabodhan Krida Bhawan  
Siddhartha Nagar, Goregaon (west) MUMBAI 400 104

CIN: LS1900MH1987PLC042141

**Corp Office:**

B1, 6-3-1090, TSR Towers Raj Bhavan Road,  
Somajiguda, Hyderabad 500 082. A.P

T +91 40 2331 0330 / 4284 / 4296

F +91 40 2339 8435

www.gayatri.co.in



**Limited Review Report**

**To**  
**The Board of Directors**  
**M/s. Gayatri Tissue and Papers Limited.**

We have reviewed the accompanying statement of unaudited financial results of M/s. Gayatri Tissue and Papers Limited for the period ended 30.06.2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N G Rao & Associates**  
Chartered Accountants  
Firm's Registration Number: 009399S



**(G. Nageswara Rao)**

Partner  
Membership No.207300

Place of Signature: Hyderabad  
Date: 25.08.2020

UDIN: 20207300AAAAND1761



## GAYATRI TISSUE & PAPERS LIMITED

Regd. Office:16/137 Siddharthanagar,Road No.5,Near Prabodhan Krida Bhavan, Goregaon(West) , MUMBAI-400 104  
UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020  
CIN: L51900MH1987PLC042141

Rs. In Lakhs

S.No.	Particulars	Quarter ended	Preceding	Quarter ended	Year Ended
		30.06.2020	quarter	30.06.2019	31.03.2020
		Un Audited	31.03.2020	Un Audited	Audited
			Audited		
<b>1</b>	<b>Income from Operations</b>				
	(a) Revenue from operations	10.06	10.02	41.73	81.85
	(b) Other Income			0.12	0.12
	<b>Total Revenue (1)</b>	<b>10.06</b>	<b>10.02</b>	<b>41.85</b>	<b>81.97</b>
<b>2</b>	<b>Expenses:</b>				
	(a) Cost of Materials Consumed	-	8.02	29.21	61.31
	(b) Purchase of stock-in-trade				
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade	2.50	(5.33)		(5.33)
	(d) Employees benefits expense	3.16	3.15	3.16	12.62
	(e) Finance costs				
	(f) Depreciation and amortisation expenses				
	(g) Manufacturing expenses				
	(h) Research & Development expenses				
	(i) Other Expenses	4.07	2.18	4.56	11.31
	<b>Total Expenses (2)</b>	<b>9.73</b>	<b>8.02</b>	<b>36.93</b>	<b>79.91</b>
<b>3</b>	<b>Profit /Loss before exceptional and extraordinary items and tax (1-2)</b>	<b>0.33</b>	<b>2.00</b>	<b>4.92</b>	<b>2.06</b>
<b>4</b>	Exceptional Items	-	-	-	-
<b>5</b>	<b>Profit before extraordinary items and tax (3-4)</b>	<b>0.33</b>	<b>2.00</b>	<b>4.92</b>	<b>2.06</b>
<b>6</b>	Extraordinary Items	-	-	-	-
<b>7</b>	<b>Profit before tax (5-6)</b>	<b>0.33</b>	<b>2.00</b>	<b>4.92</b>	<b>2.06</b>
<b>8</b>	<b>Tax Expenses:</b>				
	(1). Current tax	0.09	0.52	1.27	0.54
	(2). Deferred tax				
<b>9</b>	<b>Profit (Loss) for the period from continuing operations (7-8)</b>	<b>0.24</b>	<b>1.48</b>	<b>3.65</b>	<b>1.52</b>
<b>10</b>	Profit / Loss from discontinuing operations	-	-	-	-
<b>11</b>	Tax expenses of discontinuing operations	-	-	-	-
<b>12</b>	<b>Profit/Loss from discontinuing operations (after tax) (10-11)</b>	-	-	-	-
<b>13</b>	<b>Profit (Loss) for the period (9+12)</b>	<b>0.24</b>	<b>1.48</b>	<b>3.65</b>	<b>1.52</b>
<b>14</b>	<b>Other Comprehensive Income</b>				
	A (1). Items that will not be reclassified to profit or loss	-	-	-	-
	(2). Incometax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (1). Items that will be reclassified to profit or loss	-	-	-	-
	(2). Incometax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income (A+B)</b>	-	-	-	-
<b>15</b>	<b>Total Comprehensive Income for the period (13+14)</b>	<b>0.24</b>	<b>1.48</b>	<b>3.65</b>	<b>1.52</b>
	(comprising Profit/Loss) and other comprehensive income for the period				
<b>16</b>	<b>Paid Up Equity Capital (Face value of Rs.10/- each)</b>	150.00	150.00	150.00	150.00
<b>17</b>	<b>Reserves</b>				265.59
<b>18</b>	<b>Earning Per Equity Share (EPS):</b>				
	Basic and Diluted	<b>0.02</b>	<b>0.10</b>	<b>0.24</b>	<b>0.10</b>

**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 25th August, 2020 and the statutory auditors of the company have carried out limited review of the same.
- 2 The Company is not having any Subsidiary, Joint Ventrue and Associate, hence no consolidated results are published.
- 3 The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS 108) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
- 4 There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor complaints during the quarter.
- 5 Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place: Hyderabad.  
Date: 25.08.2020

(P. MARUTHI BABU)  
Executive Director

